Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
NCT06900114
Bacterial Infections and Mycoses, COVID-19
Tianjin, China
View Trial DetailsNCT Number: NCT04368221
Characterization of fungal infections in COVID-19 infected and mechanically ventilated patients in ICU
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
CHU Angers, Angers, France
Currently, ICU patients with ARDS, whatever the etiology, are not systematically screened for the detection of respiratory fungal infections.
Here, the protocol will be in two steps:
First step
COVID-19 patients hospitalized in ICU for ARDS will benefit for a systematic screening with a fungal respiratory syndromic panel once or twice a week from entry to discharge from ICU, with minimum 3 samples when discharge occurs after 15 days::
Complementary analysis will be performed in order to finalize the diagnostic and to differentiate between colonization and infection, with:
This second step will allow to classify infections as probable or proven according to international recommendations.
Case report form (CRF) A short but standardized CRF will be proposed to all centers in order to collect demographic data and the essential clinical and laboratory data during the survey.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Non-inclusion criteria :
Exclusion criteria
Time frame: at 12 months
Prevalence of opportunistic fungal co-infections.
Time frame: at 12 months
Determination of the median time between entry in ICU and beginning of ARDS and (i) colonization and (ii) probable/proven infection with Aspergillus, Pneumocystis jirovecii and mucormycetes
Time frame: at ICU discharge, up to 1 month
Evaluation of the time between diagnosis and targeted treatment
Time frame: At 12 months
Number of proposals for evaluation of preventive strategies if necessary, because of high incidence, in terms of chemoprophylaxis and/or environmental measures
Rennes University Hospital
Other
Acronym: MY-CO-VID
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06900114
Bacterial Infections and Mycoses, COVID-19
Tianjin, China
View Trial DetailsNCT06267326
Bacterial Infections and Mycoses, COVID-19
Cairo, Egypt
View Trial DetailsNCT04261517
Bacterial Infections and Mycoses, COVID-19
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial Details